NN3201 是一种靶向 c-Kit 的抗体-药物偶联物 (ADC),具有高亲和力 (KD = 0.19 pM),由 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (MS-U66285) 与抗 c-Kit 人源单克隆抗体 NN2101 (MS-Y91737) 偶联合成,能够快速内化并抑制 SCF 驱动的信号传导,通过递送有效载荷诱导细胞周期阻滞和凋亡 (apoptosis),且由于 FcγR 结合力降低而不表现出 Fc 介导的 ADCC 和 CDC 效应功能,在多种肿瘤模型中表现出显著的 c-Kit 依赖性抗肿瘤功效,可用于小细胞肺癌 (SCLC)、胃肠道间质瘤 (GIST) 和急性髓系白血病 (AML) 的相关研究。
NN3201
产品编号: MS-Y60703 纯度: 99.15%
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价

产品描述

NN3201 是一种靶向 c-Kit 的抗体-药物偶联物 (ADC),具有高亲和力 (KD = 0.19 pM),由 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (MS-U66285) 与抗 c-Kit 人源单克隆抗体 NN2101 (MS-Y91737) 偶联合成,能够快速内化并抑制 SCF 驱动的信号传导,通过递送有效载荷诱导细胞周期阻滞和凋亡 (apoptosis),且由于 FcγR 结合力降低而不表现出 Fc 介导的 ADCC 和 CDC 效应功能,在多种肿瘤模型中表现出显著的 c-Kit 依赖性抗肿瘤功效,可用于小细胞肺癌 (SCLC)、胃肠道间质瘤 (GIST) 和急性髓系白血病 (AML) 的相关研究。

生物实验数据

生物活性 NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM), synthesized by conjugating 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (MS-U66285) with an anti-c-Kit human monoclonal antibody NN2101 (MS-Y91737); it rapidly internalizes and inhibits SCF-driven signaling, induces cell cycle arrest and apoptosis (apoptosis) through payload delivery, exhibits no Fc-mediated ADCC or CDC effector functions due to reduced FcγR binding, demonstrates significant c-Kit-dependent antitumor efficacy in multiple tumor models, and can be used for research related to small cell lung cancer (SCLC), gastrointestinal stromal tumor (GIST), and acute myeloid leukemia (AML).
体外研究
(In Vitro)

NN3201 (1 µg/mL,1 小时) 与 c-Kit 高/中表达细胞系表现出剂量依赖性结合,在 315 pM 时达到饱和,未观察到其与 c-Kit 低表达或阴性细胞系结合。
NN3201 (1 µg/mL,0.5-24 小时) 在 c-Kit 阳性的 GIST-T1 细胞中快速 (30 分钟内) 并持续内化,信号在 24 小时内持续增强,且其内化作用依赖于 c-Kit。
NN3201 (3-7 天) 在一组 c-Kit 阳性细胞系中表现出由其 MMAE 有效载荷介导的强效且 c-Kit 依赖性细胞毒性,GI50 值分别为 0.09 nM (GIST-T1)、0.69 nM (GIST-430)、0.12 nM (GIST-430/654) 和 17.06 nM (NCI-H1048)。
NN3201 (0.01-1 µg/mL,1 小时) 剂量依赖性地降低 NCI-H1048 细胞中 SCF 介导的 c-Kit (Y719、Y568/570)、Erk1/2 和 Akt (S473) 的磷酸化,而在 GIST-430/654 细胞中仅部分抑制了 pY568/570 c-Kit 和 pErk1/2 的磷酸化。
NN3201 (1 µg/mL,1-3 天) 通过持续内化诱导 c-Kit 降解和信号抑制,从而引发细胞凋亡,其表现为 caspase-3 和 caspase-7 的裂解增加。
NN3201 (5 µg/mL,24-48 小时) 诱导细胞周期阻滞于 G2/M 期和亚 G1 期,这归因于其释放的 MMAE 有效载荷的微管 (Microtubule/Tubulin) 的破坏作用。
NN3201 (4 µg/mL,7 天) 引发了强烈的旁观者效应,该效应由 NN3201 处理的 GIST-430/654 细胞释放的游离 MMAE 介导,从而导致邻近的 c-Kit 表达水平极低的 MCF7-GFP⁺ 癌细胞死亡。

Cell Viability Assay

Cell Line: MCF7-GFP+ cells
Concentration: 4 μg/mL
Incubation Time: 7 days
Result: Exhibited negligible cytotoxicity (GI50 >20 µg/mL) against the c-Kit-negative MCF7-GFP⁺ cell line, consistent with its target-dependent mechanism and in sharp contrast to the potent activity of its free payload, MMAE (GI50 = 4.96 nM).

Cell Cycle Analysis

Cell Line: GIST-430/654 and NCI-H1048 cells
Concentration: 1 μg/mL
Incubation Time: 24 and 48 h
Result: Induced substantial cell cycle arrest at the G2/M phase and increased the sub-G1 population in both cell lines.

Western Blot Analysis

Cell Line: GIST-430/654 and MCI-H1048 cells
Concentration: 1 μg/mL
Incubation Time: 1, 2, and 3 days
Result: Induced a time-dependent degradation of c-Kit in both cell lines.
Increased levels of cleaved caspase-3 and caspase-7.
Eventually inhibited the c-Kit downstream signaling pathway by sustained internalization and degradation of the NN3201-c-Kit complex over 3 days.
体内研究
(In Vivo)

NN3201 (0.5-10 mg/kg,静脉注射,每 10 天给药一次,共 3 次;或每周给药一次,共 3 次) 在多种胃肠道间质瘤 (GIST) 和小细胞肺癌 (SCLC) 肿瘤小鼠模型中,表现出显著的 c-Kit 依赖性抗肿瘤功效。

Animal Model: Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with GIST-T1 cells
Dosage: 0.5, 1.5 and 3.0 mg/kg
Administration: i.v., Q10D x 3
Result: Completely regressed tumor volume for up to 112 days at 1.5 and 3 mg/kg, with Imatinib (MS-J72535) (100 mg/kg, p.o., Q1D x 30) only inhibited tumor progression during the treatment period.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: NOG mice (5-6 weeks old) subcutaneously injected with GIST-430/654 cells
Dosage: 1, 3 and 5 mg/kg
Administration: i.v., Q1W x 3
Result: Induced significant tumor shrinkage at 3 mg/kg and 5 mg/kg, and stably controlled until day 42 and 49, respectively.
Induced tumor growth inhibition (TGI) of 47.2% on day 21 at 1 mg/kg, which was similar to that by 30 mg/kg of Sunitinib (MS-E55855) (30 mg/kg, p.o., Q1D x 21; TGI of 45.2% on day 21).
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female NOD/SCID mice subcutaneously implanted with GS5108 tumors
Dosage: 3, 5 and 10 mg/kg
Administration: i.v., Q1W x 3
Result: Induced durable tumor stasis at 10 mg/kg, which was followed by significant tumor regression for up to 60 days.
Demonstrated superior in vivo efficacy over all standard-of-care (SoC) treatments in the 3rd line GIST models.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with NCI-H526 cells
Dosage: 1, 1.5, 2, 2.5 and 3 mg/kg
Administration: i.v., Q1W x 3
Result: Induced complete regression of the tumor with no regrowth after 70 and 84 days at 2.5 and 3 mg/kg.
Exhibited 84.9% of TGI compared to the vehicle control on day 17 at 2 mg/kg.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with NCI-H1048 cells
Dosage: 1, 3, and 5 mg/kg
Administration: i.v., Q1W x 3
Result: Showed TGI of 95.1 % on day 21 at 1 mg/kg, better than the combination of Carboplatin (MS-L77931) (60 mg/kg, i.p., day 0 and 10) and Etoposide (MS-Z04043) (3 mg/kg. i.p., day 0~4 and 10~14; TGI = 70.51% on day 21).
Induced complete tumor remission for up to 35 days and 56 days at 3 mg/kg and 5 mg/kg, respectively.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with NCI-H1048 cells
Dosage: 5 mg/kg
Administration: i.v., Q1W x 3
Result: Was able to reduce the tumor volume to below baseline, whereas neither Topotecan (MS-X01138) (0.83 mg/kg, i.p., BIW x 3) nor Irinotecan (MS-O02109) (33 mg/kg, i.v., Q1W x 3) could achieve this.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with SHP-77 cells
Dosage: 1, 3, and 5 mg/kg
Administration: i.v., Q1W x 3
Result: Exhibited no in vivo potency in SHP-77 xenografts, where c-Kit expression is negligible, confirming its c-Kit driven property.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female Hsd: Athymic Nude-Foxn1nu mice subcutaneously implanted with CTG-1252 tumors
Dosage: 1, 3, and 5 mg/kg
Administration: i.v., Q1W x 3
Result: Dose-dependently inhibited tumor growth.
Achieved 70 days of complete regression at 5 mg/kg.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female Hsd: Athymic Nude-Foxn1nu mice subcutaneously implanted with CTG-2093 tumors
Dosage: 1, 3, and 5 mg/kg
Administration: i.v., Q1W x 3
Result: Induced tumor stasis until day 27 with TGI of 84.8% at 5 mg/kg.
Induced no body weight loss but rather an increase as tumor size enlarges.
性状 液体
颜色 Colorless to light yellow

化学信息

储存&溶解度

储存方式

-80°C, protect from light

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础